Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 700, Issue 1-2, 2010, Pages 1-10

  Rogalska, Aneta ^a   Szwed, Marzena ^a   Jóźwiak, Zofia ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Aclarubicin; Apoptosis; Caspases; Necrosis; PARP; Solid tumours; TUNEL

Indexed keywords

ACLARUBICIN; CASPASE 3; CASPASE 8; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL STRAIN; CELL STRAIN A 549; CELL STRAIN HEPG2; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA FRAGMENTATION; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC 50; NICK END LABELING; PRIORITY JOURNAL; SOLID TUMOR; SPECTROFLUOROMETRY;

ACLARUBICIN; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CASPASE 3; CASPASE 8; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IN SITU NICK-END LABELING; NECROSIS; POLY(ADP-RIBOSE) POLYMERASES; TIME FACTORS;

EID: 77953912036     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2010.04.013     Document Type: Article

References (49)

1. McConkey D.J., Orrenius S. Signal transduction pathways in apoptosis. Stem Cells 1996, 14:619-631.
2. Vermeulen K., Van Bockstaele D.R., Berneman Z.N. Apoptosis: mechanisms and relevance in cancer. Ann. Hematol. 2005, 84:627-639.
3. Makin G., Dive C. Apoptosis and cancer chemotherapy. Trends Cell. Biol. 2001, 11:22-26.
4. Ferreira C.G., Epping M., Kruyt F.A., Giaccone G. Apoptosis: target of cancer therapy. Clin. Cancer Res. 2003, 8:2024-2034.
5. Vermeulen K., van D.R., Bockstaele Apoptosis: mechanisms and relevance in cancer. Ann. Hematol. 2005, 10:627-639.
6. Johnstone R.W., Reuefli A.A., Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
7. Minotti G., Menna P., Salvatorelli E., Cario G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
8. Li H.Y., Yue H., Wei X.D., Zhu X.H., Zhang Y.L., Zhang L.N., Liu Y.Y., Wang P., Fang B.J., Li Y.F., Song Y.P. The efficacy of high-dose cytarabine for patients with t(8;21) AML and with normal karyotype AML. Zhonghua Xue Ye Xue Za Zhi 2008, 29:110-112.
9. Suzushima H., Wada N., Yamasaki H., Eto K., Shimomura T., Kugimiya M.H., Horikawa K., Nishimura S., Tsuda H., Mitsuya H., Asou N. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia. Leuk. Res. 2010, 34:610-614.
10. Novik Y., Ryan L.M., Haller D.G., Asbury R., Dutcher J.P., Schutt A. Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282. Med. Oncol. 1999, 16:261-266.
11. Dobashi N., Asai O., Yano S., Osawa H., Takei Y., Yamaguchi Y., Saito T., Yamazaki H., Kobayashi T., Usui N. Aclarubicin plus behenoyl cytarabine and prednisolone for previously treated acute myeloid leukemia patients. Leuk. Lymphoma 2006, 47:2203-2207.
12. Takigawa N., Takeuchi M., Shibayama T., Yoshida I., Kawata N., Tada A., Ueoka H., Takahashi K. Successful treatment of a patient with synchronous advanced non-small cell lung cancer and acute myeloid leukemia by a combination of gefitinib, low-dose cytarabine and aclarubicin. Anticancer Res. 2005, 25:2579-2582.
13. Saito T., Takehara M., Lee R., Fujimoto T., Nishimura M., Tanaka R., Ito E., Adachi K., Kudo R. Neoadjuvant chemotherapy with cisplatin, aclacinomycin A, and mitomycin C for cervical adenocarcinoma-a preliminary study. Int. J. Gynecol. Cancer 2004, 14:483-490.
14. Kania K., Zych A., Jóźwiak Z. Involvement of reactive oxygen species in aclarubicin-induced death of human trisomic and diabetic fibroblasts. Toxicol. In vitro 2007, 21:1010-1019.
15. Teillaud J.L., Gruel N., Moncuit J., Mishal Z., Fridman W.H., Lampidis T.J., Tapiero H. Structurally different anthracyclines provoke different effects on cell cycle and tumor B cell differentiation. Biomed. Pharmacother. 1998, 52:282-290.
16. Jeannesson P., Lahlil R., Chenais B., Devy L., Gillet R., Aries A., Morceau F., Trentesaux C. Anthracyclines as tumor cell differentianting agents: effects on regulation of erythroid gene expression. Leuk. Lymphoma 1997, 26:575-587.
17. Kania K., Matławska-Wa{ogonek}sowska K., Osiecka R., Jóźwiak Z. Analysis of aclarubicin-induced cell death in human fibroblasts. Cell. Biol. Int. 2007, 31:1049-1056.
18. Dartsch D.C., Schaefer A., Boldt S., Kolch W., Marquardt H. Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis. Apoptosis 2002, 7:537-548.
19. Akashi K., Eto T., Shibuya T., Shimoda K., Harada M., Niho Y. Aclarubicin induces differentiation of leukemic progenitors in myelodysplastic syndrome cooperating with granulocyte colony-stimulating factor. Leuk. Res. 2000, 24:243-248.
20. Jankowska-Wieczorek A., Marquez L., Matsuzaki A., Hashmi H.R., Larratt L.M., Goshkov L.M., Turner A.R., Zang M.C., Edwards D.R., Kossakowska A.E. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and-2) in acute myelogenous leukemia blasts: comparison with normal bone marrow cells. Br. J. Hematol. 1999, 105:402-411.
21. Carmichael J., De Graff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of tetrazolium-based semiautomated colorimetric assay: assessment of radiosenstitivity. Cancer Res. 1987, 47:943-946.
22. Gasiorowski K., Brokos B., Kulma A., Ogorzalek A., Skorkowska K. A comparison of the methods applied to detect apoptosis in genotoxically-damaged lymphocytescultured in the presence of four antimutagens. Cell. Biol. Mol. Lett. 2001, 6:141-159.
23. Rogalska A., Koceva-Chyła A., Jóźwiak Z. Aclarubicin-induced ROS generation and collapse of mitochondrial membrane potential in human cancer cell lines. Chem. Biol. Interact. 2008, 176:58-70.
24. Li S., Zhou Y., Dong Y., Ip C. Doxorubicin and selenium cooperatively induce fas signaling in the absence of Fas/Fas ligand interaction. Anticancer Res. 2007, 27:3075-3082.
25. Filyak Y., Filyak O., Stoika R. Transforming growth factor beta-1 enhances cytotoxic effect of doxorubicin in human lung adenocarcinoma cells of A549 line. Cell Biol. Int. 2007, 31:851-855.
26. Mason K.A., Valdecanas D., Hunter N.R., Milas L. INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Investig. New Drugs 2008, 26:1-5.
27. Zhang X., Ling M.-T., Wong Y.-C., Wang X. Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis. Cancer Sci. 2007, 98:308-314.
28. Gao M., Fan S., Goldberg I.D., Laterra J., Kitsis R.N., Rosen E.M. Hepatocyte growth factor/scatter factor blocks the mitochondrial pathway of apoptosis signaling in breast cancer cells. J. Biol. Chem. 2001, 276:47257-47265.
29. Koceva A., Je{ogonek}drzejczak M., Skierski J., Kania K., Jóźwiak Z. Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation. Apoptosis 2005, 10:1497-1514.
30. Hortobágyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs 1997, 54:1-7.
31. Liang C.-H., Shiu L.-Y., Chang L.-C., Sheu H.-M., Kuo K.-W. Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells. Mol. Nutr. Food Res. 2007, 51:999-1005.
32. Boven E., de Jong J., Kuiper C.M., Bast A., van der Vijgh W.J. Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. Eur. J. Cancer 1996, 32A:1382-1387.
33. Del Bufalo D., Biroccio A., Trisciuoglio D., Bruno T., Floridi A., Aquino A., Zupi G. Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used. Eur. J. Cancer 2002, 38:2455-2462.
34. Wesierska-Gadek J., Gueorguieva M., Horky M. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin. Pol. J. Pharmacol. 2003, 55:895-902.
35. Jänicke R.U., Ng P., Sprengart M.L., Porter A.G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 1998, 273:9357-9360.
36. Yang X.T., Edgerton S., Thor A.D. Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to radiation therapy. Int. J. Oncol. 2005, 26:1675-1680.
37. Kottke T.J., Blajeski A.L., Meng X.W., Svingen P.A., Ruchaud S., Mesner P.W., Boerner S.A., Samejima K., Henriquez N.V., Chilcote T.J., Lord J., Salmon M., Earnshaw W.C., Kaufmann S.H. Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells. J. Biol. Chem. 2002, 277:804-815.
38. Wang S., Konorev E.A., Kotamraju S., Joseph J., Kalivendi S., Kalyanarman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. Intermediacy of H(2)O(2)- and p53-dependent pathways. J. Biol. Chem. 2004, 279:25535-25543.
39. Zoli W., Ulivi P., Tesei A., Fabbri F., Rosetti M., Maltoni R., Giunchi D.C., Ricotti L., Brigliadori G., Vannini I., Amadori D. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Res. 2005, 7:681-689.
40. Mc Gee M.M., Hyland E., Campiani G., Ramunno A., Nacci V., Zisterer D.M. Caspase-3 is not essential for DNA fragmentation in MCF-7 cells during apoptosis induced by the pyrrolo-1,5-benzoxazepine, PBOX-6. FEBS Lett. 2002, 515:66-70.
41. Zhou Y., Gu X., Ashayeri E., Zhang R., Sridhar R. Nicotine decreases the cytotoxicity of doxorubicin towards MCF-7 and KB-3.1 human cancer cells in culture. J. Natl. Med. Assoc. 2007, 99:319-327.
42. Park S.J., Wu C.H., Safa A.R. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways. Anticancer Res. 2004, 24:123-131.
43. Sun S.Y., Yue P., Zhou J.Y., Wang Y., Choi Kim H.R., Lotan R., Wu G.S. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem. Biophys. Res. Commun. 2001, 26:788-797.
44. Wu X.-X., Jin X.-H., Zeng Y., Mamdouh Abd El Hamed A., Kakehi Y. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression. Cancer Sci. 2007, 98:1969-1976.
45. Haynes A., Shaik M.S., Chatterjee A., Singh M. Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line. Pharmacol. Res. 2003, 20:1485-1495.
46. Kosmider B., Zyner E., Osiecka R., Ochocki J. Induction of apoptosis and necrosis in A549 cells by the cis-Pt (II) complex of 3-aminoflavone in comparison with cis-DDP. Mutat. Res. 2004, 563:61-70.
47. Barraud L., Merle P., Soma E., Lefrançois L., Guerret S., Chevallier M., Dubernet C., Couvreur P., Trépo C., Vitvitski L. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol. 2005, 42:736-743.
48. Davis D.V., Buchholz T.A., Hess K.R., Sahin A.A., Valero V., McConkey D.J. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin. Cancer Res. 2003, 9:955-960.
49. 3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene 2005, 24:761-779.